Dr. Thomas Prebet, MD, PhD

Dr. Prebet practices at Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut.

Dr. Prebet's NPI, 1811369507, was assigned on October 21, 2015. Dr. Prebet graduated from Université Claude Bernard Lyon in 2000. Dr. Prebet holds Connecticut license 54713.

Dr. Prebet's primary practice is Yale New Haven Psychiatric Hospital (York St), at 20 York Street, New Haven, CT 06510. The practice phone is (203) 688-5900.

Dr. Prebet's primary practice is Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut. Dr. Prebet is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Prebet to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Prebet practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Prebet's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Prebet is licensed in Connecticut.

CMS data shows 19 Medicare services from Dr. Prebet across 1 procedure code in 2024, all of them office visits, for 17 Medicare patients. Medicare paid $518 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 17 Medicare patients who saw Dr. Prebet in 2024. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Prebet's median patient age at 76, with 45% women.

In 2024, Dr. Prebet wrote 181 Medicare Part D claims for 24 patients. 31% of them were for generic drugs. CMS names the drug for 118 of them, across 5 drugs with 11 or more claims each, at $1,255,864 in total drug cost. In 2023, CMS named 108 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Prebet for performance year 2024, reported as part of a group. Dr. Prebet accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Prebet as offering telehealth.

Dmand AI links 115 papers to Dr. Prebet, published from 2010 to 2024. 2016 was the busiest year, with 14. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Azacitidine. Dr. Prebet has published most often in Leuk Lymphoma. Dr. Prebet's most frequent co-authors are Nikolai Alexandrovich Podoltsev, MD, PhD, Amer Zeidan and Rami Salah-Eddin Komrokji, MD.

Dmand AI links Dr. Prebet to 10 clinical trials, 5 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Myelodysplastic Syndromes. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 49 general payments to Dr. Prebet from 12 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 81% of the total. Novartis Pharmaceuticals Corporation paid the most, $35,185.

Dr. Prebet graduated from Université Claude Bernard Lyon in 2000.